Evidence map›Paper›PMID 39031387›Full record

ArticleJournal of Parkinson's disease2024

Are Preformed Fibrils a Model of Parkinson's Disease?

Amanda L Woerman, Kelvin C Luk

Abstract read
In one paragraph

Article in Journal of Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. PET imaging of alpha-synuclein: from radiotracer design through in vitro and in vivo translation.European journal of nuclear medicine and molecular imaging · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amanda L WoermanDepartment of Microbiology, Immunology, and Pathology, Prion Research Center, Colorado State University, Fort Collins, CO, USA.
Kelvin C LukDepartment of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA, USA.

Funding

Project IV "Tackling Heterogeneity of Cognitive Trajectory in LBD"U19AG062418 · NIA · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2019 to 2023
$18.1M
Propagation of Lewy pathology in Parkinsons diseaseR01NS088322 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI LUK, KELVIN C · 2015 to 2025
$4.0M
Effect of Agent and Host Factors on Alpha-Synuclein Strain PathogenesisR01NS121294 · NINDS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI Amanda L. Woerman · 2022 to 2026
$2.9M
A Novel Gene Therapy Approach to Prevent Alpha-synuclein Misfolding in Multiple System AtrophyR21NS127002 · NINDS · COLORADO STATE UNIVERSITY · PI WOERMAN, AMANDA L. · 2023 to 2024
$422k
NIA NIH HHS U19 AG062418NINDS NIH HHS R01 NS088322NINDS NIH HHS R01 NS121294NINDS NIH HHS R21 NS127002
6 · The paper itself

Abstract

Pre-formed fibrils (PFFs) made from recombinant α-synuclein are broadly used throughout the field in cellular and animal models of Parkinson's disease. However, their ability to successfully recapitulate disease biology is a controversial topic. In this article, two researchers debate this issue with Amanda Woerman taking the view that PFFs are a model of synucleinopathy but not Parkinson's disease, while Kelvin Luk defends their use as an important tool in the field.

Indexed as

alpha-SynucleinParkinson DiseaseAnimalsHumansalpha-SynucleinAlpha-synucleinParkinson’s diseasesynucleinopathies

Identifiers

PMID39031387
PMCPMC11380230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.